{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:56:16Z","timestamp":1789440976884,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.cct.2011.10.010","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T07:09:44Z","timestamp":1321254584000},"page":"320-331","source":"Crossref","is-referenced-by-count":49,"title":["A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent\/progressive glioblastoma multiforme"],"prefix":"10.1016","volume":"33","author":[{"given":"Edward","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bienemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2011.10.010_bb0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3171\/foc.2006.20.4.E1","article-title":"Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001","volume":"20","author":"Deorah","year":"2006","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.cct.2011.10.010_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cct.2011.10.010_bb0015","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0360-3016(89)90941-3","article-title":"Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma","volume":"16","author":"Wallner","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cct.2011.10.010_bb0020","first-page":"CD003913","article-title":"Chemotherapy for high-grade glioma","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cct.2011.10.010_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3171\/jns.2004.100.3.0472","article-title":"Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I\/II clinical study","volume":"100","author":"Lidar","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.cct.2011.10.010_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-009-9917-1","article-title":"Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience","volume":"95","author":"Grahn","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0040","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0045","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival","volume":"11","author":"Harrow","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP 34.5(\u2212)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.gt.3301184","article-title":"Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma","volume":"7","author":"Rampling","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.mt.6300396","article-title":"A phase I trial of Ad.hIFN-beta gene therapy for glioma","volume":"16","author":"Chiocca","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0070","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.11.138","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0075","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/10430340460732472","article-title":"Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes","volume":"15","author":"Yoshida","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.cct.2011.10.010_bb0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0090","first-page":"CD007294","article-title":"Chemotherapeutic wafers for high grade glioma","author":"Hart","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cct.2011.10.010_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-200241060-00002","article-title":"Pharmacokinetics of the carmustine implant","volume":"41","author":"Fleming","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cct.2011.10.010_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/B:NEON.0000014539.90077.db","article-title":"Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma","volume":"66","author":"Giese","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1999.90.2.0315","article-title":"Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time","volume":"90","author":"Chen","year":"1999","journal-title":"J Neurosurg"},{"key":"10.1016\/j.cct.2011.10.010_bb0110","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cct.2011.10.010_bb0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1215\/15228517-2007-007","article-title":"Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions","volume":"9","author":"Sampson","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s004320050305","article-title":"Chemosensitivity of glioma cells in vitro: a meta analysis","volume":"125","author":"Wolff","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00000421-199808000-00004","article-title":"Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme","volume":"21","author":"Gruber","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00000421-199612000-00016","article-title":"Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial","volume":"19","author":"Prados","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-008-9637-y","article-title":"Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma","volume":"90","author":"de Groot","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11060-005-9104-y","article-title":"A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma","volume":"78","author":"Tang","year":"2006","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-004-2339-1","article-title":"A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme","volume":"72","author":"Limentani","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0150","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.bjc.6602105","article-title":"Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma","volume":"91","author":"Franceschi","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cct.2011.10.010_bb0155","first-page":"2447","article-title":"Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha","volume":"22","author":"Yamamoto","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cct.2011.10.010_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/4.2.109","article-title":"A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study","volume":"4","author":"Robins","year":"2002","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00001813-200202000-00008","article-title":"Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study","volume":"13","author":"Vinolas","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cct.2011.10.010_bb0170","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0188-4409(00)00051-5","article-title":"Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: a phase II study","volume":"31","author":"Lopez-Aguilar","year":"2000","journal-title":"Arch Med Res"},{"key":"10.1016\/j.cct.2011.10.010_bb0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<362::AID-CNCR17>3.0.CO;2-X","article-title":"Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study","volume":"82","author":"Brandes","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.cct.2011.10.010_bb0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/02688699943871","article-title":"Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin","volume":"13","author":"Whittle","year":"1999","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.cct.2011.10.010_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1005856002264","article-title":"Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow","volume":"35","author":"Cloughesy","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0190","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/cncr.21112","article-title":"Enhanced chemotherapy delivery by intraarterial infusion and blood\u2013brain barrier disruption in malignant brain tumors: the Sherbrooke experience","volume":"103","author":"Fortin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cct.2011.10.010_bb0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1227\/00006123-199204000-00007","article-title":"Phase I study of intracarotid administration of carboplatin","volume":"30","author":"Stewart","year":"1992","journal-title":"Neurosurgery"},{"key":"10.1016\/j.cct.2011.10.010_bb0200","first-page":"1844","article-title":"[13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors","volume":"28","author":"Ginos","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cct.2011.10.010_bb0205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3171\/jns.2003.99.5.0893","article-title":"Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats","volume":"99","author":"Degen","year":"2003","journal-title":"J Neurosurg"},{"key":"10.1016\/j.cct.2011.10.010_bb0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/B:NEON.0000024243.31886.ab","article-title":"Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate","volume":"67","author":"Strege","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0215","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/archotol.130.12.1411","article-title":"Long-term effects of carboplatin brainstem infusions on hearing thresholds in monkeys","volume":"130","author":"May","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.cct.2011.10.010_bb0220","unstructured":"AHFS Drug Information. Monograph - carboplatin."},{"key":"10.1016\/j.cct.2011.10.010_bb0225","first-page":"F835","article-title":"Drainage of interstitial fluid from different regions of rat brain","volume":"246","author":"Szentistvanyi","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cct.2011.10.010_bb0230","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cct.2011.10.010_bb0235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","article-title":"Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study","volume":"57","author":"Patel","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cct.2011.10.010_bb0240","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clon.2007.04.003","article-title":"A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy","volume":"19","author":"Ng","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.cct.2011.10.010_bb0245","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1158\/0008-5472.CAN-05-0161","article-title":"Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring","volume":"65","author":"Mardor","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cct.2011.10.010_bb0250","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0255","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3171\/jns.2005.103.2.0311","article-title":"Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system","volume":"103","author":"Chen","year":"2005","journal-title":"J Neurosurg"},{"key":"10.1016\/j.cct.2011.10.010_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1026246500788","article-title":"Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas","volume":"65","author":"Weaver","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.cct.2011.10.010_bb0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2005.07.009","article-title":"Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen","volume":"196","author":"Krauze","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cct.2011.10.010_bb0270","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","article-title":"Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain","volume":"11","author":"Love","year":"2005","journal-title":"Nat Med"},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2011.10.010_bb0275","doi-asserted-by":"crossref","first-page":"T27","DOI":"10.1016\/j.neuroimage.2008.11.012","article-title":"Real-time MR imaging of adeno-associated viral vector delivery to the primate brain","volume":"47","author":"Fiandaca","year":"2009","journal-title":"Neuroimage"},{"issue":"8","key":"10.1016\/j.cct.2011.10.010_bb0280","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su","year":"2010","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.cct.2011.10.010_bb0285","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1227\/NEU.0b013e3181f53a5c","article-title":"Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease","volume":"67","author":"Valles","year":"2010","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.cct.2011.10.010_bb0290","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/cgt.2011.2","article-title":"Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery","volume":"18","author":"White","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cct.2011.10.010_bb0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1227\/NEU.0b013e318217217e","article-title":"T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery","volume":"69","author":"Richardson","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.cct.2011.10.010_bb0300","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2214\/AJR.06.0428","article-title":"Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin","volume":"188","author":"Sampson","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cct.2011.10.010_bb0305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3171\/2011.5.JNS11246","article-title":"Tracking accuracy of T2- and diffusion-weighted magnetic resonance imaging for infusate distribution by convection-enhanced delivery","volume":"115","author":"Iyer","year":"2011","journal-title":"J Neurosurg"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714411002758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714411002758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T13:56:16Z","timestamp":1560952576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714411002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1551714411002758"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2011.10.010","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}